Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma.

Abstract

BACKGROUND:

Outcomes for patients with metastatic Ewing sarcoma (ES) remain poor. We investigated whether the intensification of ifosfamide improved survival for patients with metastatic ES.

PROCEDURE:

We conducted a retrospective chart review of 30 patients with metastatic ES treated with the MSKCC "EFT regimen." The regimen included an intensification of ifosfamide dosing from 1,800 mg/m(2) /day × 5 days per cycle to 2,800 mg/m(2) /day × 5 days per cycle.

RESULTS:

Twenty six of the 30 patients completed planned chemotherapy. Two patients experienced disease progression during therapy. There were no toxic deaths. One patient developed secondary leukemia. The 4-year event free survival (EFS) was 27% and the overall survival (OS) was 39%.

CONCLUSIONS:

Intensification of ifosfamide was tolerated and did not increase toxicity in patients with metastatic ES. The intensification did not improve outcomes for these patients with metastatic disease.

• Authors: Heather Magnan, Christine M Goodbody, Elyn Riedel, Christine A Pratilas, Leonard H Wexler, Alexander J Chou
• Journal: Pediatric blood & cancer (Pediatr Blood Cancer) Vol. 62 Issue 4 Pg. 594-7 (Apr 2015) ISSN: 1545-5017 [Electronic] United States
• PMID: 25630954 (Publication Type: Clinical Trial, Journal Article)
• Copyright: © 2015 Wiley Periodicals, Inc.

Chemical References

• Antineoplastic Agents, Alkylating
• Ifosfamide

Topics

• Adolescent
• Adult
• Antineoplastic Agents, Alkylating (administration & dosage)
• Bone Neoplasms (drug therapy, mortality, pathology)
• Child
• Disease-Free Survival
• Female
• Follow-Up Studies
• Humans
• Ifosfamide (administration & dosage, adverse effects)
• Male
• Neoplasm Metastasis
• Sarcoma, Ewing (drug therapy, mortality, pathology)
• Survival Rate
• Time Factors